Status:
COMPLETED
PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study)
Lead Sponsor:
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Collaborating Sponsors:
Roche Pharma AG
Conditions:
Hepatocellular Cancer
Cholangiocarcinoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
PLATON (Platform for Analyzing Targetable Mutations) is a prospective, multicentre, observational cohort study with biobanking. In a first approach PLATON's pilot-study assesses genomic profiling in g...
Detailed Description
PLATON (Platform for Analyzing Targetable Mutations) is designed to improve personalized therapy for patients in different cancer entities, such as in hepatocellular cancer (HCC), intra- and extrahepa...
Eligibility Criteria
Inclusion
- Histologically confirmed diagnosis of hepatocellular carcinoma or intra-/extrahepatic cholangiocarcinoma or gallbladder carcinoma or pancreatic ductal adenocarcinoma or esophagogastric adenocarcinoma in the advanced setting and no local curative therapy available.
- Standard first line therapy is planned, or patient is currently receiving first line therapy (started within the last 2 months before enrolment)
- ECOG 0-2
- Life expectancy ≥ 6 months
Exclusion
- Not able to understand all implications of study participation
- No written informed consent
- age \< 18 years
Key Trial Info
Start Date :
October 28 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2024
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT04484636
Start Date
October 28 2020
End Date
December 31 2024
Last Update
March 20 2025
Active Locations (46)
Enter a location and click search to find clinical trials sorted by distance.
1
KHNW Frankfurt
Frankfurt am Main, Hesse, Germany, 60488
2
Hannover Medical School
Hanover, Lower Saxony, Germany, 30625
3
Onkologische Schwerpunktpraxis Speyer
Speyer, Rhineland-Palatinate, Germany, D-67346
4
Elblandklinikum Riesa
Ried, Saxony, Germany, D-01589